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Abstract
Introduction The acronym SAPHO was introduced in 1987 to
unify the various descriptions of a seronegative arthritis
associated with skin manifestations and to show synovitis, acne,
pustulosis, hyperostosis, and osteitis with and without sterile
multifocal osteomyelitis. The etiology of SAPHO syndrome is
unknown, but an association with infection by semipathogenic
bacteria like Propionibacterium acnes has been suggested. We
conducted an interventional study of SAPHO patients receiving
antibiotics.
Methods Thirty-seven patients met the clinical criteria of
SAPHO syndrome, 21 of them underwent a needle biopsy of
the osteitis lesion, and 14 of them showed positive
bacteriological cultures for P. acnes. Thirty patients (14
bacteriological positive and 16 without biopsy) were treated
with antibiotics for 16 weeks. The activity of skin disease and
osteitis were assessed by a physician using a scoring model
(from 0 to 6). In addition, patients completed a Health
Assessment Score (HAS, from 0 to 6). The erythrocyte
sedimentation rate was determined and a MRI (of the osteitis
lesion, radiologic activity score from 0 to 2) was performed in
week 1 (W1), week 16 (W16), and week 28 (W28, 12 weeks
after antibiotics).
Results Twenty-seven patients continued the medication
(azithromycin, n = 25, 500 mg twice a week; clindamycin, n = 1,
300 mg daily; or doxycycline, n = 1, 100 mg daily) for 16 weeks.
After W16 the scores for MRI (1.5 to 1.1, P = 0.01), skin activity
(3.2 to 1.2, P = 0.01), osteitis activity (4.0 to 2.1, P = 0.02), and
HAS (3.3 to 2.1, P = 0.01) decreased significantly. However,
this was followed by increasing values for MRI scores (1.2 to
1.4, P = 0.08), skin activity (1.2 to 1.7, P = 0.11), osteitis activity
(1.9 to 2.7, P = 0.01), and HAS (2.2 to 3.3, P = 0.02) from W16
to W28. The comparison of the scores in W1 and W28 in these
12 patients showed no significant differences.
Conclusions For the period of application, the antibiotic therapy
seems to have controlled the disease. After antibiotic
discontinuation, however, disease relapse was observed.
SAPHO syndrome thus groups with other chronic inflammatory
arthropathies with a need for permanent therapy.
Introduction
In 1987 Chamot and colleagues coined the acronym SAPHO
for synovitis, acne, pustulosis, hyperostosis, and osteitis,
which replaced various previously suggested descriptions of
osteoarticular disease associated with skin manifestations
[1,2]. The clinical feature of chronic recurrent multiple osteo-
myelitis (CRMO) with its typical presentation in the pediatric
population justifies the inclusion of CRMO into the same noso-
logic group as the SAPHO syndrome according to several
authors [3,4].
The etiology of these diseases is still unknown. An association
with infection by semipathogenic bacteria such as Propioni-
bacterium acnes has been suggested, but the role of thesePage 1 of 8
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of coagulase-negative Staphyloccocus aureus as well as Hae-
mophilus parainfluenzae and Actinomyces were reported to
be associated with SAPHO syndrome [7,8]. Family-based
observations and investigations of genetic variations gave rise
to the hypothesis that genetic factors contribute to the devel-
opment and course of the disease [9,10]. Moreover, SAPHO
syndrome shows a clear overlap with several inflammatory
rheumatic diseases such as ankylosing spondylitis, psoriatic
arthritis, enteropathic arthritis, reactive arthritis, and undiffer-
entiated spondyloarthritis. In 13 to 52% of SAPHO cases,
radiologic findings show sacroiliitis - as in typical ankylosing
spondylitis [11]. The genetic marker HLA-B27, however, is not
clearly associated with SAPHO syndrome [12,13]. Clinical
symptoms of psoriatic arthritis are comparable with the fea-
tures of SAPHO syndrome. In some cases, psoriasis vulgaris
has developed after initial typical skin changes in patients with
SAPHO syndrome. The skin manifestation of acne vulgaris is
not typical of psoriatic arthritis, however, and the psoriatic-typ-
ical nail dystrophy has not been reported in SAPHO patients.
Although the classification of SAPHO syndrome exists as a
distinct disease entity, the overlap and similarities with other
rheumatic diseases formed the basis for trials investigating
antirheumatic drugs that are the accepted standard for the
treatment of psoriatic arthritis and other spondyloarthritides.
Studies have been published with small numbers of patients
treated with nonsteroidal anti-inflammatory drugs [14], ster-
oids [15,16] and immunosuppressive agents that showed only
partial efficacy. Investigations of methotrexate and azathio-
prine yielded no convincing results [17,18]. Several reports
presenting promising results obtained with bisphosphonates
[19-21] or biologicals like TNFα-blockers [22,23], however,
have recently been published. With regard to the possible link
to an infectious etiology of SAPHO syndrome, several studies
with small numbers of patients treated with antibiotics
reported contradictory results [24,25]. According to these
studies, the antibiotic agent of azithromycin was suggested as
the most promising agent for treatment of patients with
SAPHO syndrome. We have therefore conducted a prospec-
tive interventional study to evaluate the efficacy of antibiotics
in patients with SAPHO syndrome.
Materials and methods
Study design
We conducted a prospective, interventional study in patients
treated at the Rheumatology Departments of the Hannover
Medical School and the Saarland University Medical School,
Germany. The responsible ethics committee of Hannover
Medical School, Germany approved the study. The study was
conducted in accordance with the Declaration of Helsinki, and
each participant gave written informed consent.
Patients
From October 1998 until February 2007 we screened 37
patients with SAPHO syndrome. All patients fulfilled the crite-
ria of SAPHO syndrome - that is, osteitis of any location with
inflammatory extra-osteoarticular manifestations of palmo-
plantar pustulosis, psoriasis vulgaris, or acne fulminans, with
or without arthritis and/or CRMO - as defined by Chamot and
colleagues [2] and by Kahn and colleagues [26].
Of 25 patients with dermatological manifestations, one patient
presented with psoriasis vulgaris, 21 patients with pustulosis
palmoplantaris, one patient with acne conglobata, and two
patients with acne papulopustulosa (Table 1). Patients with
axial disease and spondylitis were excluded in order to avoid
the inclusion of patients with ankylosing spondylitis (Bech-
terew's disease). Twenty-one patients underwent a computed
tomography-guided needle biopsy of the osteitis lesion for his-
topathological and bacteriological investigation as described
previously [27]. Inclusion criteria were age > 18 years and clin-
ical activity of SAPHO syndrome. Exclusion criteria were anti-
biotic treatment in the previous 12 weeks, women who were
pregnant or breastfeeding, patients on medication with corti-
costeroids in a higher dosage than 10 mg prednisolone or
equivalent steroids per day, psychiatric disorders that might
compromise compliance with therapy, and contraindications
for administration of azithromycin, doxycycline, and clindamy-
cin, including a history of allergy to any antibiotics.
We enrolled 37 patients with SAPHO syndrome showing dis-
ease activity as determined by a scoring system based on the
erythrocyte sedimentation rate (ESR), MRI findings, skin activ-
ity and osteitis activity (see below). All patients except those
with a negative bacteriological finding (n = 7) in the needle
biopsy of the osteitis lesion were offered treatment with azi-
thromycin (alternatively with doxycycline or clindamycin). Thirty
patients agreed to antibiotic treatment (Figure 1). Table 1
presents the demographic and clinical - pathological patient
characteristics of these treated patients.
Treatment regime
Twenty-two out of 30 patients were on antirheumatic medica-
tions without antibiotics, with a stable dosage of the respec-
tive drugs at least 4 weeks prior to the beginning of this study
(outlined in Table 2). The 27 patients treated with azithromycin
received a loading dose of 500 mg on six successive days, fol-
lowed by 500 mg twice a week. After needle biopsy of the
osteitis lesion, three patients from the antibiotics group
showed a positive bacteriological culture for P. acnes resist-
ant to azithromycin but sensitive to doxycycline in two patients
and sensitive to clindamycin in one patient. Two patients there-
fore received doxycyline (100 mg daily) and one patient
received clindamycin (300 mg daily) as the first-line antibiotic
drug. Eight patients were without concomitant antirheumatic
medication.Page 2 of 8
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antibiotics, and one patient was lost at follow-up. Two patients
dropped out because of intolerance to the antibiotic medica-
tion (one patient on azithromycin and one patient on doxycy-
cline). After the end of the antibiotic therapy, only 12 patients
completed the follow-up for a further 12 weeks, during which
they were to continue the same antirheumatic medication - the
study protocol did not allow antibiotics or any change of con-
comitant medication during this follow-up period. The remain-
ing 15 out of 27 patients who had completed the antibiotic
treatment according to the protocol were lost at follow-up (six
patients) or changed medication (five patients who took addi-
tional nonsteroidal anti-inflammatory drugs daily, two patients
who took additional corticosteroids orally, and two patients
who had topic corticoid instillation of osteitis lesion).
Definitions and assessment
In all patients the diagnosis of SAPHO syndrome was con-
firmed by the diagnostic procedure, including tests for C-reac-
tive protein and the ESR, bone radioisotope scanning with
technetium in two phases and MRI of osteitis lesions. The
scoring system was assessed within 1 week prior to the initia-
tion of the antibiotic therapy, after week 16 and in week 28 (or
12 weeks after ending antibiotic treatment), and included an
elevated sedimentation rate (ESR), MRI of osteitis lesions,
clinical activity of skin lesions and clinical activity of osteitis
lesions as well as a Health Assessment Score (HAS).
The MRI score for the osteitis lesions ranged from 0 to 2 and
was assessed by a radiologist: score 0 was defined as no
bone marrow edema, osteal erosions or synovitis (with or with-
out joint effusion) imaged by T1-weighted and T2-weighted
magnetic resonance technique; score 1 defined as one of the-
ses pathological findings; and score 2 defined as more than
one finding. In cases of more than one osteitis lesion, the
lesion with the highest score was used as reference. The radi-
ologist was blinded to the clinical scores under the treatment
during the follow-up. Both the skin activity score and the ostei-
tis score of the patients (ranging from 0 to 6) were assessed
by the treating physician according to a questionnaire for the
interview and by physical examination. The HAS was evaluated
by the patient and described the subjective disease activity
during the last 7 days before the assessment, using a scale
ranging from 0 (no activity) to 6 (highest activity).
Bacteriological findings
In all investigations the skin above the biopsy area was free of
pustulotic changes. After thorough disinfection, a small surgi-
cal skin incision of approximately 3 mm was made under local
anesthesia before the biopsy needle was advanced under
computed tomography guidance. This procedure was sup-
posed to minimise the possibility of specimen contamination
by skin colonisation of P. acnes and other skin saprophytes.
The computed tomography-guided needle biopsies of the
osteitis lesion were inoculated for transport and were referred
Table 1
Clinical characteristics of SAPHO patients on antibiotics
Clinical parameter SAPHO patients (n = 30)
Age (years)
Mean ± standard error 51.6 ± 3.3
Median (range) 51 (20 to 72)
Sex (female:male) 16/14 (53/47)
Disease duration (years)
Mean ± standard error 9.4 ± 2.5
Median (range) 11 (1 to 27)
HLA B27-positive 2 (7)
Chronic recurrent multifocal osteomyelitis 4 (14)
Biopsy of osteitis lesion with positive bacterial culture 14 (47)
> 1 osteitis lesion 11 (37)
Psoriasis 1 (3)
Pustulosis palmoplantaris 21 (70)
Acne 3 (10)
Arthritis/oligoarthritis 20 (67)
Data presented as n (%) unless stated otherwise.Page 3 of 8
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School for further work-up as previously described [27]. The
biopsies were transferred directly after grinding plated on solid
media (Schaedler's agar, chocolate agar; Oxoid Unipath,
Wesel, Germany). Media were incubated for a minimum of 14
days at 35 ± 2°C for detection of aerobic, microaerophilic, and
anaerobic microorganisms, including fastidious microorgan-
isms. Their susceptibility to antibiotics was tested according
to the National Committee for Clinical Laboratory Standard
Protocol. Bone specimens were also sent to the Department
of Pathology of Hannover Medical School for histopathologi-
cal examination. The histopathological preparation in all spec-
imens excluded malignant cell proliferation.
Statistical analysis
The study had two major end points: the change of scores for
the ESR, MRI, the HAS, skin activity and osteitis activity after
16 weeks of antibiotics; and the changing of scores after the
end of the antibiotic treatment period. All data were analysed
using the SPSS statistical package [28]. Quantitative varia-
bles are expressed as the mean ± standard error. The scoring
variables outlined in the mean ± standard error were com-
pared using pairwise testing for differences between the
results for scores of weeks 1 and 16, of weeks 16 and 28, as




The demographic and clinical - pathological characteristics of
the 30 patients selected for antibiotic treatment are presented
in Table 1.
Outcome after treatment in week 16
Table 3 presents the results of the SAPHO disease activity in
27 patients before and after the treatment with antibiotics in
week 1 and week 16. After week 16, the scores for MRI (1.5
to 1.1, P = 0.01), for skin activity (3.2 to 1.2, P = 0.01), for
Figure 1
Flow chart from initial study enrollment to study follow-up for the treatment of SAPHO syndrome.Page 4 of 8
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P = 0.01) decreased significantly in the antibiotics group.
Outcome 12 weeks after the end of the antibiotic 
treatment
Table 4 presents the outcome 12 weeks after the end of anti-
biotic treatment (week 28 after beginning of the study) of the
12 SAPHO patients who completed the follow-up for whom
the activity scores were available at that time point. As shown
in the table, compared with week 16, the follow-up scores in
week 28 were increased with the respect to the MRI scores
(1.2 to 1.4, P = 0.08), the skin activity scores (1.2 to 1.7, P =
0.11), the osteitis activity scores (1.9 to 2.7, P = 0.01), and the
HAS (2.2 to 3.3, P = 0.02) from week 16 to week 28 (Figure
2). The comparison of the scores in week 1 and week 28 in
these 12 patients, however, resulted in no significant differ-
ences: skin activity scores, 2.5 to 1.7 (P = 0.09); osteitis activ-
ity scores, 3.5 to 2.7 (P = 0.15); ESR, 24.8 to 25.7 (P = 0.34);
MRI scores, 1.6 to 1.4 (P = 0.19); and HAS, 3.8 to 3.3 (P =
0.11).
Discussion
To the best of our knowledge, this is the first interventional
study to evaluate the efficacy of long-term antibiotic treatment
in patients with SAPHO syndrome. The goal of the present
study was to determine the therapeutic effect of antibiotic
treatment over a period of 4 months. Our results show an
effect of a 4-month treatment with azithromycin (also with dox-
ycycline and clindamycin in one patient each) with respect to
MRI findings and to the activity of skin disease and osteitis.
Three months after the end of antibiotic treatment, however,
these effects had disappeared. The observed changes in the
SAPHO activity scores were so closely associated with the
antibiotic treatment that a placebo effect is rather unlikely.
Studies that include a placebo control group, however, are
required in order to clarify the efficacy of antibiotic therapy of
SAPHO syndrome.
Azithromycin was chosen as the first-line therapy because of a
broad spectrum of antimicrobial activity that has been shown
in vitro to be highly concentrated in various phagocytic cells
and to be active against bacteria within these cells [29]. The
uptake and magnitude of concentrations of the antibiotic in
phagocytes over extended periods of time were therefore sup-
posed to be interesting, particularly for the treatment of ostei-
tis. Furthermore, the accumulation of azithromycin in
phagocytic cells is suggested to contribute to a more effective
eradication of phagocytised bacterial organisms [30]. Moreo-
ver, macrolids are known to have a wide range of anti-inflam-
matory mechanisms besides their antibiotic properties
[31,32]. In line with these results, previous studies demon-
strated that clinical isolates of P. acnes were highly suscepti-
ble to azithromycin. To what extent the change of SAPHO
activity observed in our study was due to a specific antibiotic
effect or a more antiphlogistic effect of the antibiotics, or both,
cannot be derived from our data [33].
There are only few studies investigating the effect of antibiotic
treatment in a small number of SAPHO patients. Bellara and
colleagues described two patients with SAPHO syndrome
with a positive response to long-term doxycylin treatment [34].
Schaeverbeke and colleagues reported one case of success-
ful treatment of a SAPHO patient with azithromycin [35]. In
Table 2
Antirheumatic treatment of SAPHO patients on antibiotics at 
baseline
Medication except antibiotics SAPHO patients (n = 30)
No medication 8 (27)
Nonsteroidal anti-inflammatory drugsa 10 (33)
Prednisolone 2 (7)
Dosage (mg/day) 5.0 (4.0 to 6.0)
Sulfasalazineb 1 (3)
Methotrexate 8 (27)
Dosage (mg/week) 12.8 (10.0 to 15)
Etanerceptc 3 (10)
Bisphosphonated 3 (10)
Data presented as n (%) or mean (range). aNonsteroidal anti-
inflammatory drugs in a stable daily dosage: diclofenac, 100 or 150 
mg daily; naproxen, 1,000 or 1,500 mg daily; ibuprofen, 800, 1,200 
or 1,600 mg daily; celecoxib, 200 mg daily. bSulfasalzine in a dosage 
of 2 g daily. cEtanercept in a dosage of 50 mg weekly. dAlendronat in 
a weekly dosage of 70 mg.
Table 3
Activity scores of SAPHO patients in weeks 1 and 16 with antibiotic treatment
Activity score Week 1 Week 16 P value (95% confidence interval)a
Skin 3.2 ± 0.4 (0 to 6) 1.2 ± 0.3 (0 to 4) 0.01 (1.29 to 2.64)
Osteitis 4.0 ± 0.3 (2 to 6) 2.1 ± 0.3 (0 to 6) 0.02 (1.25 to 2.40)
Erythrocyte sedimentation rate 24.1+-2.6 (9 to 45) 22.8+-3.1 (11 to 38) 0.34+-2.9 (- 0.20 to 0.53)
MRI 1.5 ± 0.1 (0 to 2) 1.1 ± 0.1 (0 to 2) 0.01 (0.24 to 0.88)
Health Assessment Score 3.3 ± 0.8 (0 to 6) 2.1 ± 0.4 (0 to 6) 0.01 (1.43 to 2.49)
Data presented as the mean ± standard error (range); n = 27. aPairwise test (value week 1 vs. value week 16).Page 5 of 8
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with sulfamethoxazole/trimetoprim was previously described
[7]. Kirchhoff and colleagues presented data for seven
patients being treated successfully with azithromycin over 5
months [27]. A successful antibiotic treatment with azithromy-
cin was also described for patients with CRMO [24]. For the
time being, these case reports and uncontrolled observations
are consistent with our results.
The treatment regimes of the present study included in most
of the patients a combination therapy of conventional antirheu-
matic drugs and antibiotics. Based on the specific pharmaco-
Figure 2
Activity scores and erythrocyte sedimentation rate values (mean) of 12 SAPHO patients treated with antibiotics. *differences of the values between 
week 1 and week 16: P < 0.05; **differences of the values between week 16 and week 28: P < 0.05; HAS = Health Assessment score; ESR = 
Erythrocyte sedimentation rate; MRI = Magnet resonance imaging.
Table 4
Activity scores in weeks 1, 16 and 28 for SAPHO patients treated with antibiotics
Activity score Week 1 Week 16 Week 28 P value (95% confidence interval)
Skin 2.5 ± 0.5 (1 to 6) 1.2 ± 0.5 (0 to 4) 1.7 ± 0.5 (0 to 5) 0.01 (1.31 to 2.77)a
0.11 (-1.43 to -0.24)b
0.09 (-0.17 to 1.84)c
Osteitis 3.5 ± 0.4 (1 to 6) 1.9 ± 0.4 (0 to 4) 2.7 ± 0.5 (0 to 6) 0.01 (1.30 to 2.63)a
0.01 (-1.43 to -0.24)b
0.15 (-0.31 to 1.81)c
Erythrocyte sedimentation rate 24.8+-3.3 (9 to 45) 23.3+-2.8 (11 to 36) 25.7+-2.4 (12 to 40) 0.43 (-0.13 to 0.30)a
0.35 (-0.33 to 0.13)b
0.34 (-0.20 to 0.53)c
MRI 1.6 ± 0.1 (0 to 2) 1.2 ± 0.1 (0 to 2) 1.4 ± 0.2 (1 to 2) 0.01 (0.44 to 0.89)a
0.08 (-0.54 to 0.04)b
0.19 (-0.15 to 0.65)c
Health Assessment Score 3.8 ± 0.4 (2 to 6) 2.2 ± 0.3 (0 to 6) 3.3 ± 0.4 (1 to 6) 0.01 (1.51 to 2.79)a
0.02 (2.02 to 0.32)b
0.11 (-0.16 to 1.32)c
Treatment finishing in week 16. Data presented as the mean ± standard error (range); n = 12. aPairwise test (value week 1 vs. value week 16). 
bPairwise test (value week 16 vs. value week 28). cPairwise test (value week 1 vs. value week 28).Page 6 of 8
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methotrexate, potential drug interaction was expected. No
specific side effects of these drug combinations were
detected, however, in the present study population of SAPHO
patients. Whether the efficacy of antibiotics was possibly
altered (weakened or increased) cannot be derived from our
data.
Whereas the majority of papers concerning antibiotic therapy
in infectious diseases report a clear association between dis-
ease duration and success of antibiotic treatment, the data for
this study population cannot determine such effects because
of the heterogeneity of the disease duration, ranging from 1 to
27 years.
One important result of our present study data is the disap-
pearance of the antibiotic treatment effect after discontinua-
tion of these drugs. Osteitis activity and the HAS increased
statistically significantly, while skin activity and the MRI find-
ings showed a strong trend towards increasing values. The
comparison of the scores in week 28 with week 1 shows no
statistically significant differences, indicating a return to base-
line values after the end of antibiotic treatment. SAPHO syn-
drome, however, can be considered a basically relapsing -
remitting disease. For this reason the data presented here can-
not definitely exclude that a deterioration of the disease activity
after antibiotic discontinuation could also be associated with a
relapse of disease regardless of the antibiotic therapy. Never-
theless, the correlation between the ending of antibiotic ther-
apy and increasing disease activity appears to be plausible.
This correlation is further supported by the fact that 9 out of 27
patients were excluded from the study because of a change in
antirheumatic medication between week 16 and week 28. In
these patients an intensification of antirheumatic therapy was
required to treat the deterioration of SAPHO syndrome activ-
ity. Combined, these data place SAPHO syndrome in a range
of chronic inflammatory arthropathies with a potential need for
permanent therapy, and raise the question of whether there is
a need for discussion of how to prevent microbial resistance
and disease escape by periodical drug administration or dis-
continuation.
Conclusions
For the period of application the antibiotic therapy appears to
control the disease activity of SAPHO syndrome, whereas dis-
continuation of antibiotic therapy seems to be associated with
disease deterioration. In what way a permanent administration
of antibiotic therapy (beyond 4 months) is a promising treat-
ment option for SAPHO syndrome cannot be derived from our
data.
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